Page 24 - Gene Therapy Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors Passage BioFebruary 19, 2021 GMT PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the appointment of Maxine Gowen, Ph.D., to its board of directors, effective Feb. 18. Dr. Gowen is chief executive officer of Tamuro Bio, a post that she has held since July 2...

Fred Hutch, Univ. of Washington biotech spinout Ensoma launches with $70M in funding February 11, 2021 at 9:15 am Dr. Hans-Peter Kiem of the Fred Hutchinson Cancer Research Center. (Fred Hutch Photo) New spinout: Boston-based biotech startup Ensoma launched Thursday and announced a $70 million Series A funding round. The company is built on technology developed over two decades by Seattle researchers Dr. Hans-Peter Kiem of the Fred Hutchinson Cancer Research Center and Dr. André Lieber of the University of Washington School of Medicine. The company will be based in Boston because the city �...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of ... Passage BioFebruary 8, 2021 GMT - Phase 1/2 trial expected to commence in first half of 2021  - Company has three INDs cleared for rare monogenic CNS disorders PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the U.S....

Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses Further Validates Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies to Develop Next Generation Gene Therapies PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Fabry disease in mice. The results are featured in a virtual poster presentation at the 17th Annual WORLDSymposium™ 2021, being ...

New gene-based vaccine strategy receives grant from the Bill & Melinda Gates Foundation The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation. The grant will aid the effort to bring further preclinical validation to the AAV vaccine platform. An AAVCOVID vaccine candidate is set to enter clinical trials in 2021. The AAVCOVID vaccine program was founded at Mass General Brigham at the outset of the pandemic. Preliminary tests of the vaccines' stab...